Literature DB >> 2306803

Attenuation of vasopressin-mediated coronary constriction and myocardial depression in the hypoxic heart.

W A Boyle1, L D Segel.   

Abstract

To investigate the ability of arginine vasopressin (AVP) to compete with metabolic vasodilatory factors in the coronary circulation, we examined the coronary vascular and myocardial effects of AVP in isolated working rat hearts during normoxic and hypoxic perfusion. In normoxic hearts, AVP treatment (777 +/- 67 pg/ml) reduced coronary flow by 38.4 +/- 2.6%. Myocardial function was also significantly decreased by AVP whereas efficiency significantly increased. In contrast, the same dose of AVP administered to hypoxic hearts resulted in substantially smaller effects on coronary flow (-11.5 +/- 2.8%), myocardial function, and efficiency. In hearts treated first with AVP and then with hypoxia, the greater degree of coronary vasodilation compared with that observed in hearts treated with hypoxia alone also indicated an antagonizing effect of hypoxia on AVP-mediated coronary constriction. It was also noted that the hypoxia treatment alone resulted in reductions of O2 supply and consumption identical to those produced by AVP treatment during normoxia. However, hypoxia was associated with a significantly greater effect on myocardial function and, in contrast to the effect of AVP, a marked reduction in efficiency. The rate of lactate release was greater during hypoxia alone (2.07 +/- 0.08 mumol/min) than with AVP treatment during normoxia (0.76 +/- 0.05 mumol/min). These results indicate that the effect of AVP on the coronary vessels, as well as its effect on the myocardium, is significantly attenuated during hypoxia. In addition, AVP-constricted vessels appear to retain considerable vasodilatory reserve despite evidence of ischemic conditions. Thus, although the effects of AVP resemble ischemia, the increased efficiency and the relatively small effect of AVP on contractile function, as well as the preserved vasodilatory reserve, suggest otherwise. A physiological explanation for these observations is proposed wherein the constricting effects of AVP modulate the effects of autoregulatory factors such that blood flow requirements are minimized while allowing preservation of adequate blood flow for vital tissue function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306803     DOI: 10.1161/01.res.66.3.710

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  8 in total

1.  Vasopressin and oxytocin release during prolonged environmental hypoxia in the rat.

Authors:  H Kelestimur; R M Leach; J P Ward; M L Forsling
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

2.  Vasopressin as an adjunct therapy for pulmonary hypertension: a case report.

Authors:  Andra Malikiwi; Arun Sasi; Kenneth Tan; Arvind Sehgal
Journal:  Eur J Pediatr       Date:  2013-12-03       Impact factor: 3.183

Review 3.  Cardiac efficiency.

Authors:  J D Schipke
Journal:  Basic Res Cardiol       Date:  1994 May-Jun       Impact factor: 17.165

Review 4.  Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology.

Authors:  Cheryl L Holmes; Donald W Landry; John T Granton
Journal:  Crit Care       Date:  2003-06-26       Impact factor: 9.097

Review 5.  Hypothalamic-Pituitary-Adrenal Axis Modulation of Glucocorticoids in the Cardiovascular System.

Authors:  Natalie G Burford; Natalia A Webster; Diana Cruz-Topete
Journal:  Int J Mol Sci       Date:  2017-10-16       Impact factor: 5.923

Review 6.  Complementary Role of Oxytocin and Vasopressin in Cardiovascular Regulation.

Authors:  Ewa Szczepanska-Sadowska; Agnieszka Wsol; Agnieszka Cudnoch-Jedrzejewska; Tymoteusz Żera
Journal:  Int J Mol Sci       Date:  2021-10-24       Impact factor: 5.923

7.  Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine.

Authors:  Sangeeta Mehta; John Granton; Anthony C Gordon; Deborah J Cook; Stephen Lapinsky; Gary Newton; Kris Bandayrel; Anjuli Little; Chuin Siau; Dieter Ayers; Joel Singer; Terry C K Lee; Keith R Walley; Michelle Storms; D James Cooper; Cheryl L Holmes; Paul Hebert; Jeffrey Presneill; James A Russell
Journal:  Crit Care       Date:  2013-06-20       Impact factor: 9.097

8.  Distribution and relative expression of vasoactive receptors on arteries.

Authors:  Xinhao Liu; Dan Luo; Jie Zhang; Lei Du
Journal:  Sci Rep       Date:  2020-09-21       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.